or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Although major breakthroughs in the field of pediatric cardiology, cardiac surgery,
intervention, and overall care improved the outlook of congenital heart disease …

Background: Eisenmenger syndrome describes congenital heart disease-associated severe
pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double …

Background Pulmonary arterial hypertension (PAH) is a rare disease characterized by
distinctive changes in pulmonary arterioles that lead to progressive pulmonary arterial …

Aims We aimed to assess the contemporary outcome of Eisenmenger syndrome (ES),
delineate the use of disease targeting therapies (DTT) in these patients and to investigate …

Pulmonary arterial hypertension (PAH) is a disease with complex pathobiology, significant
morbidity and mortality, and remains without a cure. It is characterized by vascular …

Background Pulmonary arterial hypertension (PAH) is common in patients with congenital
heart disease (CHD). Although Eisenmenger syndrome may be on decline, other types of …

Congenital heart disease (CHD), the most common inborn defect, affects approximately 1%
of all newborns worldwide. Advances in its diagnosis and treatment have led to a dramatic …

Background Positron emission tomography (PET) imaging with radiolabeled fibroblasts
activation protein inhibitor (FAPI) provides the opportunity to directly visualize fibrosis. This …

Echocardiography is the mainstay in screening for pulmonary hypertension (PH).
International guidelines suggest echocardiographic parameters for suspecting PH, but these …